A Look At Xeris Biopharma Holdings (XERS) Valuation After Its Profit Turnaround And Guidance Hike

Xeris Biopharma Holdings (XERS) stock is in focus after the company reported a profitable first quarter of 2026 and raised its full year revenue guidance to US$380 million to US$390 million.

See our latest analysis for Xeris Biopharma Holdings.

The guidance hike and first quarter profit have come after a mixed period for the stock, with a 12.95% 1 month share price return and a 9.80% year to date share price decline. At the same time, 1 year and 3 year total shareholder returns of 28.49% and around 13x respectively point to stronger longer term momentum.

If this kind of earnings driven move has your attention, it could be a useful moment to see what else is moving in healthcare and biotech via 35 healthcare AI stocks

With shares still below analyst targets and the stock scoring weakly on value metrics, the key question now is whether Xeris Biopharma is trading at a discount or whether the latest guidance hike is already fully reflected in the price.

Most Popular Narrative: 40.5% Undervalued

The most followed valuation work on Xeris Biopharma Holdings currently places fair value at $11.14 per share versus a last close of $6.63, framing a sizable implied gap that depends on how its products and pipeline convert into future cash generation.

Persistent high gross margins, alongside scaling sales of Gvoke, Recorlev, and Keveyis, are viewed as setting the stage for operational leverage and sustainable EBITDA and net margin changes as revenue changes and expense ratios change over time.

Read the complete narrative.

Want to see what is behind that confidence in future cash generation? The narrative refers to faster revenue growth, rising margins, and a richer earnings multiple to reach its fair value.

Result: Fair Value of $11.14 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, that upside view still runs into real questions around Xeris Biopharma's reliance on just a few commercial products and the cost of advancing its XP-8121 pipeline program.

Find out about the key risks to this Xeris Biopharma Holdings narrative.

Another View: High P/E Points to Rich Pricing

That 40.5% implied discount sits alongside a very different message from the P/E ratio. Xeris Biopharma trades on a P/E of 95.3x, compared with a 16.7x industry average, a peer average of around negative 37.2x, and a fair ratio of 25x. This combination signals meaningful valuation risk if expectations slip.

For a closer look at how this stacks up, including what the numbers imply for potential rerating risk, see the full breakdown via See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Mixed signals on value and risk can be confusing, so check the underlying data while it is fresh in the market and weigh both sides through 3 key rewards and 1 important warning sign

Looking for more investment ideas?

If you only focus on one stock, you could miss other opportunities that fit your style, so consider putting a few high quality ideas on your radar using these tools.

• Target quality at a discount by scanning a curated set of 51 high quality undervalued stocks that combine attractive pricing with solid fundamentals.
• Prioritise resilience by filtering for 71 resilient stocks with low risk scores that score well on stability and balance sheet strength.
• Get ahead of the crowd by searching a screener containing 23 high quality undiscovered gems before they appear on more radars.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com